Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)
334.60
+0.00 (0.00%)
NASDAQ · Last Trade: Apr 3rd, 8:04 AM EDT
Detailed Quote
Previous Close
334.60
Open
-
Bid
318.01
Ask
340.00
Day's Range
N/A - N/A
52 Week Range
189.00 - 377.46
Volume
4
Market Cap
5.72B
PE Ratio (TTM)
-15.22
EPS (TTM)
-22.0
Dividend & Yield
N/A (N/A)
1 Month Average Volume
358,719
About Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)
Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for liver and metabolic diseases, with an emphasis on addressing non-alcoholic steatohepatitis (NASH) and related conditions. The company’s research and development efforts center around its proprietary drug candidates that target and modulate key metabolic pathways, aiming to improve patient outcomes and provide effective treatment options. By leveraging cutting-edge science and clinical expertise, Madrigal is dedicated to advancing its pipeline of transformative therapies to meet the growing needs of patients suffering from complex liver diseases. Read More
The launch of Madrigal Pharmaceuticals Inc.’s NASH drug Rezdiffra exceeded all expectations in the recent quarterly earnings release. The stock rose more than 50% in a few days – and the company now has a market cap of close to $8 billion.
